Acceleron Starts Clinical Trial of Novel Bone Loss Treatment
Posted on: Friday, 23 June 2006, 06:00 CDT
Acceleron Pharma, a biopharmaceutical company involved in the development of regenerative therapeutics, has initiated a phase I clinical trial of ACE-011, a novel treatment for bone loss disease, particularly osteoporosis.
Acceleron said it will start the first regenerative therapeutic to enter human clinical trials from Acceleron's scientific platform that utilizes the body's own naturally-occurring growth factors.
"Based on extensive evidence from preclinical studies, ACE-011 has the potential to rebuild bone even after substantial bone loss has already occurred. The preclinical data strongly suggests that ACE-011 could fundamentally change the treatment of bone loss," said Dr Jasbir Seehra, chief scientific officer and a founder of Acceleron.
Acceleron is conducting the phase I study in healthy post-menopausal women. The study is a randomized, placebo-controlled, a single ascending dose study designed to evaluate safety, tolerability, and pharmacology properties of ACE-011.
Following the phase I study of ACE-011, Acceleron will introduce other regenerative drug candidates into clinical development and will continue to build integrated pharmaceutical capabilities to develop these candidates into new therapies.
Source: Datamonitor
Related Articles
- Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients With Multiple Myeloma
- LifeCycle Pharma Announces Positive Topline Results From Phase II Clinical Study of LCP-Tacro Once Daily in Stable Liver Transplant Patients
- ACE-011 Preclinical Data Published in the Proceedings of the National Academy of Sciences
- BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results From Phase III Clinical Trial of Tavocept(TM)
- Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination With Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Oramed Pharmaceuticals Successfully Completes Animal Studies for Phase 1B Clinical Trials Of Its Oral Insulin Capsule
- Radius Begins Phase II Clinical Trial of BA058 for Osteoporosis
- Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss; Acceleron Becomes a Clinical-Stage Company
- Vitae Pharmaceuticals Initiates Phase II Clinical Trials for Two Novel Compounds for Psoriasis and Cancer Conditions
- Therion Biologics Corporation Completes Enrollment in Phase II Clinical Trial of PROSTVAC(R)-VF in Androgen Independent Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds